pillbase.ru

Besponsa

Active substance: inotuzumab ozogamicin

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · INOTUZUMAB OZOGAMICIN .25 mg/mL

United StatesActive

Marketing holder: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 2
  • Биспонса
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 1 мг, 1 мг (original in Russian, GRLS)
    ЛП-№(000413)-(РГ-RU)
    Пфайзер Инк
  • Биспонса
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 1 мг, (original in Russian, GRLS)
    ЛП-005883
    Пфайзер Инк.
EU 1
  • Besponsa
    Inotuzumab ozogamicin
    EMEA/H/C/004119
    Pfizer Europe MA EEIG
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-35c1-7bd1-892a-dfb4dc30d5f3,01a120c5-d710-7379-9254-094ece38cc4f;count=2 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208f-a9e6-7da2-8932-fe82734b79be;count=1 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
0008-0100
Registration status
Active
Dispensing
Prescription only
Route
INTRAVENOUS
Sources
  • product · openFDA NDC · 0008-0100 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 0008-0100 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 0008-0100 · Verified 2026-10-09 · open in source